Arvinas Reports Results of ARV-471 in P-I/II Study for the Treatment of Breast Cancer
Shots:
- The P-II (VERITAC) cohort expansion part of the P-I/II clinical study evaluates ARV-471 (200/500mg) vs ARV-471 + palbociclib in patients with locally advanced/metastatic ER+/HER2- breast cancer. The 1EPs of the study include CBR & 2EPs include ORR, DOR, PFS & OS
- The results demonstrated antitumor activity in all CDK4/6 inhibitor pre-treated patients as measured by a CBR of 38% (n=71) in patients with mutant ESR1 tumors (n=41) depicting 51.2% & those with ESR1 wild-type tumors (n=25) depicting 20%
- Additionally, all patients depicted an mPFS of 3.7mos. & 5.7mos. for those with mutant ESR1 tumors. ARV-471 is a PROTAC protein degrader designed to specifically target & degrade the ER
Ref: Arvinas | Image: Arvinas
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
